---
title: "TuHURA Biosciences (HURA) news: merger"
url: "https://aibio.space/companies/tuhura-biosciences/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "HURA merger news: TuHURA Biosciences completes Kineta acquisition, paying 0.185298 TuHURA share per Kineta share. TuHURA Biosciences, Inc."
---

HURA TuHURA Biosciences, Inc. NASDAQ · United States

# TuHURA Biosciences (HURA) news HURA merger news

Debt Financing · 2026-10-09

## [TuHURA Biosciences draws $650,000 more on Parkview credit line](https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line-2/)

TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million.

## Latest TuHURA Biosciences news

1. 2026-09-21 Debt Financing [TuHURA Biosciences draws another $650,000 on Parkview credit line](https://aibio.space/news/tuhura-biosciences-draws-another-650-000-parkview-credit-line/) Parkview Holdings One LLC is the lender. The $650,000 draw is small against $27.6 million of cash used in operations in 2025, and TuHURA reported $995,977 in cash and cash equivalents at June 30, 2026.
2. 2026-09-14 Debt Financing [TuHURA Biosciences makes $650,000 draw on Parkview credit line](https://aibio.space/news/tuhura-biosciences-makes-650-000-draw-parkview-credit-line/) TuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026.
3. 2026-09-02 Debt Financing [TuHURA Biosciences borrows $1,500,000 under Parkview revolving facility](https://aibio.space/news/tuhura-biosciences-borrows-1-500-000-under-parkview-revolving-facility/) The company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031.
4. 2026-08-19 Financings [TuHURA Biosciences, Inc. stockholders approve 1,878,287 loan fee shares for Parkview](https://aibio.space/news/tuhura-biosciences-inc-stockholders-approve-1-878-287-loan-fee-shares/) TuHURA Biosciences' stockholders approved on August 18, 2026 the issue of 1,878,287 shares to its lender, Parkview Holdings One LLC, as a fee for a $50 million revolving credit facility. The company's cash stood at $995,977 on June 30, 2026, according to its quarterly report.
5. 2026-08-07 Debt Financing [TuHURA Biosciences draws $650,000 more on its Parkview credit line](https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line/) The draw is part of a revolving credit facility of up to $50 million with Parkview Holdings One LLC that matures in April 2031.
6. 2026-07-28 Debt Financing [TuHURA Biosciences draws $1,500,000 on its Parkview revolving credit facility](https://aibio.space/news/tuhura-biosciences-draws-1-500-000-parkview-revolving-credit-facility/) TuHURA Biosciences borrowed $1,500,000 more under its $50 million revolving facility with Parkview Holdings One LLC. The filing gives no interest rate for the draw and flags conflicts of interest tied to the lender.
7. 2026-06-30 Debt Financing [TuHURA Biosciences borrows $1,900,000 more under Parkview credit line](https://aibio.space/news/tuhura-biosciences-borrows-1-900-000-more-under-parkview-credit-line/) TuHURA Biosciences drew an additional $1,900,000 under its revolving credit facility with Parkview Holdings One LLC. The facility matures April 21, 2031 and allows up to $50 million in borrowing, and the filing does not describe its interest rate or collateral.
8. 2026-05-26 Debt Financing [TuHURA takes first $1,700,000 draw on Parkview revolving credit facility](https://aibio.space/news/tuhura-takes-first-1-700-000-draw-parkview-revolving-credit-facility/) The $50 million revolving facility from Parkview Holdings One LLC matures in April 2031. The company expects to use the first draw for general corporate purposes.
9. 2025-09-11 Financings [TuHURA Biosciences investors agree to buy $3.2 million of deferred stock now](https://aibio.space/news/tuhura-biosciences-investors-agree-buy-3-2-million-deferred-stock-now/) Four investors who could defer their purchases until December 31, 2025 agreed to buy now. In return, TuHURA extended warrants on 1.5 million shares to December 31, 2030.
10. 2025-06-30 Mergers [TuHURA Biosciences completes Kineta acquisition, paying 0.185298 TuHURA share per Kineta share](https://aibio.space/news/tuhura-biosciences-completes-kineta-acquisition-paying-0-185298-tuhura/) TuHURA closed its merger with Kineta on June 30, 2025, issuing about 2,868,169 shares at closing, with about 1,129,885 more due after six months, subject to adjustment. The deal adds the antibody TBS-2025, for which the press release reports tolerability and receptor occupancy but no efficacy results.
11. 2025-06-30 Mergers [TuHURA Biosciences completes acquisition of Kineta in all-stock deal](https://aibio.space/news/tuhura-biosciences-completes-acquisition-kineta-all-stock-deal/) Each Kineta share converts into 0.185298 TuHURA shares, or 2,868,169 shares in total, with 1,129,885 more due after six months. The release gives no cash balance or loss figure.
12. 2024-11-25 Mergers [TuHURA Biosciences signs letter of intent to acquire Kineta's KVA12123](https://aibio.space/news/tuhura-biosciences-signs-letter-intent-acquire-kinetas-kva12123/) The letter is non-binding and the release states no price. TuHURA targets a definitive agreement in Q4 2024 and completion of the acquisition in H1 2025.

## TuHURA Biosciences at a glance

- **Ticker**: HURA

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $995,977

### Related companies

- [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) NASDAQ: KLRA
- [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) NASDAQ: VIR
- [Denali Therapeutics](https://aibio.space/companies/denali-therapeutics/) NASDAQ: DNLI
- [LeonaBio](https://aibio.space/companies/leonabio/) NASDAQ: LONA
- [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) NASDAQ: STOK
- [GB Sciences](https://aibio.space/companies/gb-sciences/) OTC: GBLX
- [Absci](https://aibio.space/companies/absci/) NASDAQ: ABSI
- [Instil Bio](https://aibio.space/companies/instil-bio/) NASDAQ: TIL

### Also on NASDAQ

- [Xenetic Biosciences](https://aibio.space/companies/xenetic-biosciences/) XBIO
- [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) SRRK
- [ANGIODYNAMICS INC](https://aibio.space/companies/angiodynamics/) ANGO
- [uniQure](https://aibio.space/companies/uniqure-n-v/) QURE
- [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA
- [Ensysce Biosciences](https://aibio.space/companies/ensysce-biosciences/) ENSC

## TuHURA Biosciences annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) | [$0](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) |
| Research and development | [$20.5 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) | [$13.3 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) |
| Net income (loss) | [-$30.1 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) | [-$21.7 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) |
| Cash from operations | [-$27.6 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) | [-$14.7 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) |
| Cash and equivalents | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526350451/) | [$12.7 million](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $995,977.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about TuHURA Biosciences

Is TuHURA Biosciences involved in a merger or acquisition?

Our latest story on this, dated Jun 30, 2025: "TuHURA Biosciences completes Kineta acquisition, paying 0.185298 TuHURA share per Kineta share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tuhura-biosciences-completes-kineta-acquisition-paying-0-185298-tuhura/).

What is the ticker symbol of TuHURA Biosciences?

TuHURA Biosciences, Inc. trades under the ticker HURA on NASDAQ.

Where is TuHURA Biosciences listed?

TuHURA Biosciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PL3; LS:A3EWMJ; LSX:A3EWMJ.

What is the SEC CIK of TuHURA Biosciences?

The SEC Central Index Key (CIK) for TuHURA Biosciences, Inc. is 1498382. Its filings are on SEC EDGAR.

How many shares does TuHURA Biosciences have outstanding?

63,726,617 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is TuHURA Biosciences listed under?

Our directory records TuHURA Biosciences, Inc. under United States.

What does TuHURA Biosciences do?

Our directory classifies TuHURA Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of TuHURA Biosciences?

The ISIN recorded for TuHURA Biosciences, Inc. is US8989201038.

Does aibio.space cover TuHURA Biosciences?

aibio.space lists TuHURA Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is TuHURA Biosciences incorporated?

SEC records list its state or country of incorporation as NV.

What was TuHURA Biosciences's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is TuHURA Biosciences profitable?

TuHURA Biosciences, Inc. reported a net loss of $30.1 million for the fiscal year ended Dec 31, 2025, and used $27.6 million of cash in operations, per its annual report to the SEC.

How much does TuHURA Biosciences spend on research and development?

$20.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does TuHURA Biosciences have?

$995,977 in cash at Jun 30, 2026, per its 10-Q.

What is the latest TuHURA Biosciences (HURA) stock news?

Our latest story on TuHURA Biosciences, dated Oct 9, 2026: "TuHURA Biosciences draws $650,000 more on Parkview credit line". TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million. [Source](https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line-2/).

## Investor discussion: TuHURA Biosciences

Members talk about TuHURA Biosciences (HURA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TuHURA Biosciences, newest first. Each line links the filing it comes from.

1. 2026-08-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312526357087/hura-20260818.htm)
2. 2026-04-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312526168395/d139552dex991.htm)
3. 2026-04-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312526147660/d131347dex991.htm)
4. 2026-04-08 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312526147748/d134632d424b5.htm)
5. 2026-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/hura-20251231.htm)
6. 2026-01-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312526031742/hura-20260129.htm)
7. 2025-12-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312525313799/d27148d424b5.htm)
8. 2025-11-18 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/d851083dex991.htm)
9. 2025-11-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312525263523/hura-20251103.htm)
10. 2025-09-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000095017025114235/hura-20250905.htm)
11. 2025-08-12 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312525179009/d898723ds1.htm)
12. 2025-06-30 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000095017025091693/hura-ex99_1.htm)
13. 2025-06-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000095017025089118/hura-ex99_1.htm)
14. 2025-04-01 Mergers Reported a merger or acquisition agreement. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1498382/000119312525069713/d888264d425.htm)
15. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1498382/000095017025047921/hura-20241231.htm)
16. 2025-01-03 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000095017025001330/hura-20241227.htm)
17. 2024-11-25 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/hura-ex99_1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HURA on TradingView](https://www.tradingview.com/symbols/NASDAQ-HURA/).

## SEC filings and registration

- **SEC name**: TuHURA Biosciences, Inc./NV

- **CIK**: 1498382

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: HURA (Nasdaq)

- **State or country of incorporation**: NV

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 10500 UNIVERSITY CENTER DR., TAMPA, FL, 33612

- **Phone**: 813-875-6600

- **Shares outstanding**: 63,726,617 as of 2026-08-11 (10-Q filed 2026-08-14)

- **Former names**: Kintara Therapeutics, Inc.; DelMar Pharmaceuticals, Inc.; Berry Only Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526424228/hura-20261009.htm) filed 2026-10-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526401140/hura-20260921.htm) filed 2026-09-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526394473/hura-20260914.htm) filed 2026-09-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526393206/hura-20260910.htm) filed 2026-09-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526383797/hura-20260902.htm) filed 2026-09-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526361272/hura-20260820.htm) filed 2026-08-21
- [8-K](https://www.sec.gov/Archives/edgar/data/1498382/000119312526357087/hura-20260818.htm) filed 2026-08-19
- [10-Q](https://www.sec.gov/Archives/edgar/data/1498382/000119312526350451/hura-20260630.htm) filed 2026-08-14

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001498382), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

TuHURA Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HURA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: TuHURA Biosciences, Inc.

- **Ticker**: HURA

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US8989201038

- **Other listed symbols**: GETTEX:PL3; LS:A3EWMJ; LSX:A3EWMJ

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HURA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/tuhura-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TuHURA Biosciences (HURA) news: merger", 2026-10-31, https://aibio.space/companies/tuhura-biosciences/